Pasireotide Research for Acromegaly
An evidence-based overview of research examining Pasireotide in the context of acromegaly. This page synthesizes findings from peer-reviewed literature.
Research Summary
FDA-approved for acromegaly in 2014. PAOLA trial demonstrated superiority over octreotide LAR in SSA-resistant patients (31.3% vs 19.2% biochemical control, p=0.007). Also superior as first-line medical therapy in treatment-naive patients. Particularly effective in tumors with high SSTR5 expression.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Pasireotide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.